Literature DB >> 1703682

Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.

J J Fung1, S Todo, A Tzakis, A Demetris, A Jain, K Abu-Elmaged, M Alessiani, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1703682      PMCID： PMC2954599     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  13 in total

Review 1.  Cyclosporine.

Authors:  B D Kahan
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

2.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Transplantation.

Authors:  T E Starzl; J J Fung
Journal:  JAMA       Date:  1990-05-16       Impact factor: 56.272

4.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

5.  Studies on the mechanism of action of cyclosporin A.

Authors:  D Wiesinger; J F Borel
Journal:  Immunobiology       Date:  1980-01       Impact factor: 3.144

6.  A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.

Authors:  M W Harding; A Galat; D E Uehling; S L Schreiber
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

7.  Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy.

Authors:  N Murase; D G Kim; S Todo; D V Cramer; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1990-08       Impact factor: 4.939

8.  Liver, kidney, and thoracic organ transplantation under FK 506.

Authors:  S Todo; J J Fung; T E Starzl; A Tzakis; A J Demetris; R Kormos; A Jain; M Alessiani; S Takaya; R Shapiro
Journal:  Ann Surg       Date:  1990-09       Impact factor: 12.969

9.  Isolation and amino acid sequence of cyclophilin.

Authors:  M W Harding; R E Handschumacher; D W Speicher
Journal:  J Biol Chem       Date:  1986-06-25       Impact factor: 5.157

10.  The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase.

Authors:  G Fischer; H Bang
Journal:  Biochim Biophys Acta       Date:  1985-03-22
View more
  37 in total

1.  History of clinical transplantation.

Authors:  T E Starzl
Journal:  World J Surg       Date:  2000-07       Impact factor: 3.352

2.  Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients.

Authors:  A Jain; R Venkataramanan; S Todo; K Abu-Elmagd; J Fung; V Warty; A Tzakis; J Reyes; M Alessiani; T E Starzl
Journal:  Transplant Proc       Date:  1992-06       Impact factor: 1.066

3.  The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.

Authors:  J J Fung; M Eliasziw; S Todo; A Jain; A J Demetris; J P McMichael; T E Starzl; P Meier; A Donner
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

4.  Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.

Authors:  A C Tsamandas; S M Pham; E C Seaberg; O Pappo; R L Kormos; A Kawai; B P Griffith; A Zeevi; R Duquesnoy; J J Fung; T E Starzl; A J Demetris
Journal:  J Heart Lung Transplant       Date:  1997-07       Impact factor: 10.247

5.  FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation.

Authors:  A G Tzakis; K Abu-Elmagd; J J Fung; E J Bloom; B Nour; F Greif; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

6.  Interaction between FK506 and clotrimazole in a liver transplant recipient.

Authors:  L Mieles; R Venkataramanan; I Yokoyama; V J Warty; T E Starzl
Journal:  Transplantation       Date:  1991-12       Impact factor: 4.939

7.  Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients.

Authors:  I Felser; S Wagner; J Depee; N Johnson; S Staschak; A Jain; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

8.  FK 506 versus cyclosporine in pediatric liver transplantation.

Authors:  A G Tzakis; J Reyes; S Todo; M Green; T Ohya; A Jain; K Abu-Elmagd; M Alessiani; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 9.  Notes on FK 506.

Authors:  T E Starzl; J Fung; S Todo; A Tzakis
Journal:  Transplant Proc       Date:  1991-08       Impact factor: 1.066

10.  The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver.

Authors:  K Abu-Elmagd; J J Fung; M Alessiani; A Jain; R Venkataramanan; V S Warty; S Takaya; S Todo; W D Shannon; T E Starzl
Journal:  Transplantation       Date:  1991-07       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.